Aktana and Cantab Pi Bring Together 2M+ Data Sets and Predictive Analytics at Scale to Optimize HCP Engagement
16.11.2021 16:13:00 EET | Business Wire | Press release
Aktana, the leader in intelligent customer engagement for the global life sciences industry, announced a new partnership with Cantab Pi, a data science company based in Cambridge, UK. Founded to address the unique data needs of European markets, Cantab Pi brings dynamic targeting capabilities and more than two million healthcare professional (HCP) profiles from a range of sources, including social media and clinical journals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005444/en/
Investment in artificial intelligence (AI) and machine learning continues to grow across the commercial life sciences industry, but many companies limit its use to a single region or brand—never maximizing the value of their investments. Cantab Pi’s sophisticated analytical models and social listening tools allow life sciences organizations to sharpen digital targeting and optimize their omnichannel marketing mix—even in markets where traditional HCP-level data is commercially unavailable. Combined with Aktana’s scalable intelligent engagement platform, the partnership offers life sciences companies deeper insights for orchestrated omnichannel engagement with HCPs across all customer-facing teams, brands, therapeutic areas, and geographies.
Novartis, a leader in digital transformation, will be the first to implement the blended solution. “We have a business imperative to harness as much intelligence as possible from the wealth of data we manage,” said Paul Thompson, global director of AI enablement and orchestration at Novartis. “This new program is part of our continued mission to find innovative ways to segment, engage and follow up with our customers.”
“With the increased use of digital technology, multiple channels, and heightened expectation for consumer-like engagement, the industry needs intelligence engines to personalize and coordinate customer engagement,” said Siniša Slijepčević, founder and CEO at Cantab Pi. “By feeding models with daily insights from the channels where HCPs are engaging most, like Twitter, companies more accurately personalize campaigns and see double or triple digital engagement as a result. With Aktana, we enable life sciences organizations to optimize HCP relationships, increase efficiency, and better support physicians.”
With more than 300 combined deployments, Aktana and Cantab Pi bring proven technologies to the life sciences industry. In addition to Aktana’s Contextual Intelligence platform, new offerings include social media listening tools that aggregate more than 500 data points daily across more than two million HCP social media profiles and dynamic targeting models. For commercial teams, this translates to near real-time insights delivered in their daily workflows on the digital and scientific influence of Key Opinion Leaders (KOLs), HCP affinity for digital engagement, and social media indicators for future sales. The partnership also allows teams to optimize their marketing mix using machine learning and predictive modeling.
“One of the exciting challenges for the industry right now is in identifying the highest-value data sets, building robust predictive models and then having the ability to deploy them on a multi-product/country scale,” said Graham Rapier, vice president, EMEA markets at Aktana. “The Cantab Pi and Aktana partnership provides a powerful solution for this by bringing together comprehensive HCP clinical influence data, advanced marketing mix analytics, and a globally scalable intelligence and orchestration platform.”
About Aktana
Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com.
About Cantab Pi
Cantab Pi, founded in 2017 in Cambridge, UK, provides innovative Predictive Analytics, Machine Learning and Artificial Intelligence for life sciences, with a focus on marketing and sales. Cantab Pi is already empowering multiple brands on three continents for some of the leading global pharma companies and the most innovative biotechs. Cantab Pi’s vision is to bring together rich external data sources, deep understanding of business needs, state-of-the art analytics, and agile deployment of its Machine Learning as a Service platform, to boost productivity of sales teams and customer engagement. For more information, visit www.cantabpi.com/life-sciences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005444/en/
Contact information
Media Contacts:
Aktana
Lisa Barbadora
610-420-3413
lbarbadora@barbadoraink.com
Cantab Pi
Andrijana Kos Kavran
andrijana.kos.kavran@itfactory.hr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 16:15:00 EEST | Press release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale9.10.2026 16:00:00 EEST | Press release
Ada, the pioneer in Agentic Customer Experience, today announced it has achieved the Amazon Web Services (AWS) Travel and Hospitality Competency. The designation recognizes Ada as an AWS Partner with demonstrated technical proficiency and proven customer success helping travel and hospitality brands resolve customer issues at scale. Ada joins a select group of 58 AWS Partners holding the competency, and it reflects a shared commitment to helping travel brands deliver service that holds up on their busiest, most unpredictable days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009673638/en/ Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale "Travel is where agentic customer service gets tested hardest. Demand spikes without warning, policies change by the hour, and customers are often stressed and far from home," said Mike Murchison, CEO and co-founder of Ada. "Our airline and hospitali
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
